FOLH1 and neoplasm: 177Lutetium-PSMA-617, a PSMA ligand labelled with a beta-emitting radionuclide lutetium-177, accumulates at PSMA expressing tumor sites, inducing cancer cell death, and has recently been shown to be effective for men with advanced PSMA-positive CRPC [39].